Overview: NGS ALS Sequencing TestIntroduction: The NGS ALS Sequencing Test sequences genes to diagnose amyotrophic lateral sclerosis (ALS), causing muscle weakness or paralysis. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected ALS.
Other Names: ALS Assay, SOD1/C9orf72 Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: ALS sequencing began in the 1990s with motor neuron disease research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose ALS, guides treatment, and evaluates patients with muscle weakness or paralysis.
Test Parameters: 1. ALS Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of muscle weakness, paralysis, or ALS symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document muscle weakness, paralysis, dysarthria, or family history of ALS. Include current medications, especially riluzole.
Consent: Written consent required, detailing the tests purpose, ALS implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze ALS genes (e.g., SOD1, C9orf72). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for ALS diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm ALS, guiding supportive care or clinical trials. Negative results may require EMG or other testing.
Specialist Consultation: Consult a neurologist for result interpretation and treatment planning.
Additional Supporting Tests: EMG, nerve conduction studies, or MRI to confirm ALS diagnosis.
Test Limitations: Not all ALS cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN ALS Guidelines, 2023; Neurology, Brown RH, 2022.
